Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2013 Mar;27(3):731-4.
doi: 10.1038/leu.2012.223. Epub 2012 Aug 3.

Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children's Oncology Group Study POG 9421

M M O'Brien, X Cao, S Pounds, G V Dahl, S C Raimondi, N J Lacayo, J Taub, M Chang, H J Weinstein, Y Ravindranath, H Inaba, D Campana, C H Pui, J E Rubnitz
Multicenter Study

Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children's Oncology Group Study POG 9421

M M O'Brien et al. Leukemia. 2013 Mar.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) Event-free survival according to leukemia subtypes in patients treated on AML02. The 3-year rates were 100% for the 5 patients with the t(1;22) AMKL, 85.8% ± 6.1% for the 57 patients with favorable cytogenetics [t(8;21) or inv(16)], 56.1% ± 5.3% for the 135 patients with other AML subtypes, and 36.3% ± 10.9% for the 21 AMKL patients without the t(1;22) (P=0.023) (b) Overall survival according to leukemia subtypes in patients treated on AML02. The 3-year rates were 100% for the 5 patients with t(1;22) AMKL, 90.6% ± 5.1% for the 57 patients with favorable cytogenetics [t(8;21), inv(16)], 66.1% ± 5% for the 135 patients with other AML subtypes, and 42.4% ± 11.4% for the 21 AMKL patients without t(1;22) (P<0.001).
See this image and copyright information in PMC

References

    1. Athale UH, Razzouk BI, Raimondi SC, Tong X, Behm FG, Head DR, et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood. 2001 Jun 15;97(12):3727–3732. - PubMed
    1. Barnard DR, Alonzo TA, Gerbing RB, Lange B, Woods WG. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group. Pediatr Blood Cancer. 2007 Jul;49(1):17–22. - PubMed
    1. Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol. 2006 Sep 20;24(27):4499–4506. - PubMed
    1. Reinhardt D, Diekamp S, Langebrake C, Ritter J, Stary J, Dworzak M, et al. Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment. Leukemia. 2005 Aug;19(8):1495–1496. - PubMed
    1. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010 Jun;11(6):543–552. - PMC - PubMed

Publication types

MeSH terms